Prime-Boost Immunization of Codon Optimized HIV-1 CRF01_AE Gag in BCG with Recombinant Vaccinia Virus Elicits MHC Class I and II Immune Responses in Mice

Promkhatkaew, Duanthanorm; Pinyosukhee, Nadthanan; Thongdeejaroen, Wilai; Teeka, Jantima; Wutthinantiwong, Preeda; Leangaramgul, Preecha; Sawanpanyalert, Pathom; Warachit, Paijit

doi:10.3109/08820130903070544

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vaccinated mice produced high levels of anti-hemagglutinin antibodies that were protective against a homologous influenza virus challenge (Ramsay, 1997). Later on, extensive studies using prime-boost strategy against HIV-1, 2 were carried out using protein-vaccinia virus vaccination (Promkhatkaew et al, 2009), DNA-adenovirus vaccination (Asmuth et al, 2010), DNA-FPV vaccination (Radaelli et al, 2007), and others. Stronger immune responses especially the higher cellular immunity was obtained from these experiments suggesting a promising prospect for the prime-boost strategy in vaccine development.…”

Section: Discussionmentioning

confidence: 99%

Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing HIV-2 Gag-gp105

Song¹,

Zhang²,

Wang³

et al. 2010

View full text Add to dashboard Cite

Human immunodeficiency viruses 1 and 2 (HIV-1, 2) present a public health problem for which there is neither an effective antiviral therapy nor a preventive vaccine. In this study, the immune responses of mice to prime-boost vaccination with the recombinant DNA (rDNA) and recombinant Fowlpox virus (rFPV) both expressing HIV-2 Gag-gp105 chimeric protein, were compared to those elicited by each vector alone. Mice primed with the rDNA and boosted with the rFPV showed HIV-2-specific antibody levels, splenic CD4 + and CD8 + T-lymphocyte numbers, and Gag-gp105-specific cytotoxic T-lymphocytes (CTL) activity increased by 20-30% as compared with those elicited by these vaccines alone. These findings suggested that the prime-boost strategy combining rDNA and rFPV elicited significant Gag-gp105-specific cellular and humoral immune responses, thus supporting this novel approach to the immunization against HIV infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing HIV-2 Gag-gp105

Song¹,

Zhang²,

Wang³

et al. 2010

View full text Add to dashboard Cite

show abstract

“…BCG possesses several attributes that make it a highly favorable candidate for development as a recombinant vaccine vector. These include its ability (i) to express transgenic antigens from pathogens, such as HIV, (ii) to induce strong T-cell responses associated with the release of gamma interferon (IFN-␥) and other Th 1 cytokines, and (iii) to generate T-cell responses specific for transgenic antigens, which can ultimately be increased by heterologous boost vaccination (1)(2)(3)(4)(5)(6)(7)(8). The aforementioned responses are generated with high doses of recombinant BCG (rBCG).…”

mentioning

confidence: 99%

Role for Gr-1⁺Cells in the Control of High-Dose Mycobacterium bovis Recombinant BCG

Panas

Letvin

2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Mycobacterium bovis bacillus Calmette-Guérin (BCG) is an attractive target for development as a live vaccine vector delivering transgenic antigens from HIV and other pathogens. Most studies aimed at defining the clearance of BCG have been performed at doses between 10 2 and 10 4 CFU. Interestingly, however, recombinant BCG (rBCG) administered at doses of >10 6 CFU effectively generates antigen-specific T-cell responses and primes for heterologous boost responses. Thus, defining clearance at high doses might aid in the optimization of rBCG as a vector. In this study, we used bioluminescence imaging to examine the kinetics of rBCG transgene expression and clearance in mice immunized with 5 ؋ 10 7 CFU rBCG expressing luciferase. Similar to studies using low-dose rBCG, our results demonstrate that the adaptive immune response is necessary for long-term control of rBCG beginning 9 days after immunizing mice. However, in contrast to these reports, we observed that the majority of mycobacterial antigen was eliminated prior to day 9. By examining knockout and antibody-mediated depletion mouse models, we demonstrate that the rapid clearance of rBCG occurs in the first 24 h and is mediated by Gr-1 ؉ cells. As Gr-1 ؉ granulocytes have been described as having no impact on BCG clearance at low doses, our results reveal an unappreciated role for Gr-1 ؉ neutrophils and inflammatory monocytes in the clearance of high-dose rBCG. This work demonstrates the potential of applying bioluminescence imaging to rBCG in order to gain an understanding of the immune response and increase the efficacy of rBCG as a vaccine vector. Mycobacterium bovis bacillus Calmette-Guérin (BCG) is an attenuated mycobacterial vaccine administered to newborns for the prevention of childhood miliary tuberculosis. BCG possesses several attributes that make it a highly favorable candidate for development as a recombinant vaccine vector. These include its ability (i) to express transgenic antigens from pathogens, such as HIV, (ii) to induce strong T-cell responses associated with the release of gamma interferon (IFN-␥) and other Th 1 cytokines, and (iii) to generate T-cell responses specific for transgenic antigens, which can ultimately be increased by heterologous boost vaccination (1-8). The aforementioned responses are generated with high doses of recombinant BCG (rBCG). Specifically, rBCG administered to mice at a dose equal to 10 6 CFU rapidly induces the development of transgene product-specific T cells, a response not observed using lower doses of 10 3 to 10 6 CFU (9-11). Furthermore, rBCG doses of Ͼ10 7 CFU induce detectable primary T-cell responses directed against the foreign transgenic epitope in rhesus macaque studies, responses that are not observed at lower doses (5,12).Despite the fact that transgene-product specific T cells are generated in response to high doses of rBCG, very few experiments have been performed to determine the clearance of high-dose BCG. Instead, experiments determining the clearance of BCG have been done using lower doses of...

show abstract

Advances and challenges in recombinantMycobacterium bovisBCG-based HIV vaccine development: lessons learned

Kilpeläinen

Maya-Hoyos

Saubí

et al. 2018

Expert Review of Vaccines

View full text Add to dashboard Cite

Prime-Boost Immunization of Codon Optimized HIV-1 CRF01_AE Gag in BCG with Recombinant Vaccinia Virus Elicits MHC Class I and II Immune Responses in Mice

Cited by 3 publications

References 29 publications

Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing HIV-2 Gag-gp105

Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing HIV-2 Gag-gp105

Role for Gr-1⁺Cells in the Control of High-Dose Mycobacterium bovis Recombinant BCG

Advances and challenges in recombinantMycobacterium bovisBCG-based HIV vaccine development: lessons learned

Contact Info

Product

Resources

About

Prime-Boost Immunization of Codon Optimized HIV-1 CRF01_AE Gag in BCG with Recombinant Vaccinia Virus Elicits MHC Class I and II Immune Responses in Mice

Cited by 3 publications

References 29 publications

Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing HIV-2 Gag-gp105

Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing HIV-2 Gag-gp105

Role for Gr-1+Cells in the Control of High-Dose Mycobacterium bovis Recombinant BCG

Advances and challenges in recombinantMycobacterium bovisBCG-based HIV vaccine development: lessons learned

Contact Info

Product

Resources

About

Role for Gr-1⁺Cells in the Control of High-Dose Mycobacterium bovis Recombinant BCG